SG11202111908XA - Intrathecal and intravenous combination gene therapy for the treatment of infantile batten disease - Google Patents
Intrathecal and intravenous combination gene therapy for the treatment of infantile batten diseaseInfo
- Publication number
- SG11202111908XA SG11202111908XA SG11202111908XA SG11202111908XA SG11202111908XA SG 11202111908X A SG11202111908X A SG 11202111908XA SG 11202111908X A SG11202111908X A SG 11202111908XA SG 11202111908X A SG11202111908X A SG 11202111908XA SG 11202111908X A SG11202111908X A SG 11202111908XA
- Authority
- SG
- Singapore
- Prior art keywords
- intrathecal
- treatment
- gene therapy
- batten disease
- combination gene
- Prior art date
Links
- 208000031277 Amaurotic familial idiocy Diseases 0.000 title 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 238000007913 intrathecal administration Methods 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 title 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 title 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962840360P | 2019-04-29 | 2019-04-29 | |
PCT/US2020/030427 WO2020223322A1 (en) | 2019-04-29 | 2020-04-29 | Intrathecal and intravenous combination gene therapy for the treatment of infantile batten disease |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111908XA true SG11202111908XA (en) | 2021-11-29 |
Family
ID=73029200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111908XA SG11202111908XA (en) | 2019-04-29 | 2020-04-29 | Intrathecal and intravenous combination gene therapy for the treatment of infantile batten disease |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220193268A1 (en) |
EP (1) | EP3963081A4 (en) |
JP (1) | JP2022530264A (en) |
KR (1) | KR20220046513A (en) |
CN (1) | CN114269935A (en) |
AU (1) | AU2020264438A1 (en) |
BR (1) | BR112021021632A8 (en) |
CA (1) | CA3138274A1 (en) |
IL (1) | IL287608A (en) |
MX (1) | MX2021013275A (en) |
SG (1) | SG11202111908XA (en) |
WO (1) | WO2020223322A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024011115A1 (en) * | 2022-07-06 | 2024-01-11 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus delivery of cln1 polynucleotide |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103038343A (en) * | 2010-03-23 | 2013-04-10 | 英特瑞克斯顿股份有限公司 | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof. |
CA3024536A1 (en) * | 2016-06-13 | 2017-12-21 | The University Of North Carolina At Chapel Hill | Optimized cln1 genes and expression cassettes and their use |
-
2020
- 2020-04-29 CN CN202080047719.4A patent/CN114269935A/en active Pending
- 2020-04-29 BR BR112021021632A patent/BR112021021632A8/en not_active Application Discontinuation
- 2020-04-29 SG SG11202111908XA patent/SG11202111908XA/en unknown
- 2020-04-29 MX MX2021013275A patent/MX2021013275A/en unknown
- 2020-04-29 CA CA3138274A patent/CA3138274A1/en not_active Abandoned
- 2020-04-29 WO PCT/US2020/030427 patent/WO2020223322A1/en unknown
- 2020-04-29 AU AU2020264438A patent/AU2020264438A1/en active Pending
- 2020-04-29 JP JP2021564486A patent/JP2022530264A/en active Pending
- 2020-04-29 US US17/607,315 patent/US20220193268A1/en active Pending
- 2020-04-29 EP EP20798198.6A patent/EP3963081A4/en active Pending
- 2020-04-29 KR KR1020217038864A patent/KR20220046513A/en unknown
-
2021
- 2021-10-27 IL IL287608A patent/IL287608A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3963081A1 (en) | 2022-03-09 |
CA3138274A1 (en) | 2020-11-05 |
MX2021013275A (en) | 2022-03-17 |
JP2022530264A (en) | 2022-06-28 |
IL287608A (en) | 2021-12-01 |
CN114269935A (en) | 2022-04-01 |
EP3963081A4 (en) | 2023-07-26 |
BR112021021632A8 (en) | 2022-06-28 |
US20220193268A1 (en) | 2022-06-23 |
KR20220046513A (en) | 2022-04-14 |
AU2020264438A1 (en) | 2021-12-16 |
BR112021021632A2 (en) | 2021-12-21 |
WO2020223322A1 (en) | 2020-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291488A (en) | Gene therapy composition and treatment of right ventricular arrythmogenic cardiomyopathy | |
SG11202100022SA (en) | Gene therapy vectors for treatment of danon disease | |
IL284554A (en) | Gene therapy constructs for treating wilson disease | |
ZA202206743B (en) | Therapy for the treatment of cancer | |
EP3924371A4 (en) | Gene therapy vectors for treatment of danon disease | |
IL280684A (en) | Non-disruptive gene therapy for the treatment of mma | |
SG11202101819QA (en) | Gene therapy for the treatment of galactosemia | |
IL285647A (en) | Material and system for the therapeutic treatment of joints | |
IL285452A (en) | New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine | |
GB202114972D0 (en) | Gene therapy | |
IL287608A (en) | Intrathecal and intravenous combination gene therapy for the treatment of infantile batten disease | |
EP4100404A4 (en) | Methods and compounds for the treatment of genetic disease | |
EP4038180C0 (en) | Treatment of chronic granulomatous disease | |
EP4043012A4 (en) | Drug for treating artery-related diseases, and use thereof | |
GB202003618D0 (en) | Gene Therapy | |
EP4013414A4 (en) | Combined transgene and intron-derived mirna therapy for treatment of sca1 | |
GB201905301D0 (en) | Gene therapy | |
IL306119A (en) | Gene therapy for treating beta-hemoglobinopathies | |
GB2590793B (en) | Cannabidiol-C1 for use as a medicament and in the treatment of epilepsy | |
GB202002202D0 (en) | Gene therapy | |
GB201918879D0 (en) | Treatment of chronic pain | |
GB202005321D0 (en) | Gene therapy treatment | |
GB2603379B (en) | Avocatin B for the treatment of diseases and conditions | |
GB202215198D0 (en) | Gene therapy treatment | |
IL310017A (en) | Retgc gene therapy |